Completed PHASE3 INTERVENTIONAL 2-arm NCT00338312

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.

Sponsor: Warner Chilcott

Conditions Hypoactive Sexual Desire Disorder

Interventions Placebo patch Testosterone Transdermal System

Updated 6 times since 2017 Last updated: Apr 15, 2013 Started: Jun 30, 2002 Primary completion: Dec 31, 2004 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00338312, this PHASE3 trial focuses on Hypoactive Sexual Desire Disorder and remains completed. Sponsored by Warner Chilcott, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Warner Chilcott

Data source: Warner Chilcott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States